130 related articles for article (PubMed ID: 30300679)
21. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
He K; Xu T; Xu Y; Ring A; Kahn M; Goldkorn A
Int J Cancer; 2014 Jan; 134(1):43-54. PubMed ID: 23784558
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Lee JT; Steelman LS; McCubrey JA
Cancer Res; 2004 Nov; 64(22):8397-404. PubMed ID: 15548710
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
[TBL] [Abstract][Full Text] [Related]
24. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
[TBL] [Abstract][Full Text] [Related]
25. The role of the PI3K-AKT pathway in melanoma.
Davies MA
Cancer J; 2012; 18(2):142-7. PubMed ID: 22453015
[TBL] [Abstract][Full Text] [Related]
26. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
27. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells.
Neri LM; Borgatti P; Tazzari PL; Bortul R; Cappellini A; Tabellini G; Bellacosa A; Capitani S; Martelli AM
Mol Cancer Res; 2003 Jan; 1(3):234-46. PubMed ID: 12556562
[TBL] [Abstract][Full Text] [Related]
28. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
29. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
30. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
31. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.
Liu J; Pan C; Guo L; Wu M; Guo J; Peng S; Wu Q; Zuo Q
J Hematol Oncol; 2016 Aug; 9(1):76. PubMed ID: 27581375
[TBL] [Abstract][Full Text] [Related]
32. INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.
Chen H; Li H; Chen Q
Biochem Biophys Res Commun; 2016 Aug; 477(3):467-72. PubMed ID: 27318090
[TBL] [Abstract][Full Text] [Related]
33. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
34. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
[TBL] [Abstract][Full Text] [Related]
35. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
[TBL] [Abstract][Full Text] [Related]
36. Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor.
Fateye B; Wan A; Yang X; Myers K; Chen B
Photodiagnosis Photodyn Ther; 2015 Mar; 12(1):19-26. PubMed ID: 25636781
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
Toulany M; Rodemann HP
Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967
[TBL] [Abstract][Full Text] [Related]
38. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
39. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
40. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
Provenzano A; Kurian S; Abraham J
Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
